Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Expanded Program on Immunization


Background and Definition
Expanded Program on Immunization (EPI), established in 1987, aimes at guaranteeing the right of every child in Lebanon, regardless of social status or parent's education level, on immunization and protection from diseases that have available effective and safe vaccines. In order to ensure that, the Ministry of Public Health guarantees the provision of vaccines in  700 health care centers, public and social, in collaboration with the private sector and with the conitnuous awareness of care givers about the importance of immunization. The program provides further special attention to chidlren residing in remote and underprivileged areas through quality outreach activities.
 
EPI ِAims at:
  1. Elevating routine vaccination coverage per district to above 95%.
  2. Preserving Lebanon as polio-free, considering the continuous influx of Syrian refugees and in preparation to the eradication of polio in the region and worldwide.
  3. Eradicating Measles and Rubella by the end of year 2018.
 
EPI Activities:
  1. Continuous training and capacity building throughout the year for health care workers on routine vaccination management and implementation in all districs.
  2. Continuous work to keep Lebanon certified polio-free
  3. Implementation of the RED STRATEGY to reach every child, which includes:
    1. Data on the immunization coverage for children under one year of age
    2. Data on immunization coverage in Lebanon
    3. Identification of the number of drop-outs and planning to ensure their vaccination per district accordingly
  4. Celebrating World Immunization Week and planning awareness sessions over Lebanon about routine vaccination 
  5. Conducting National and Mop-Up Immunization campaigns annually, including vaccination against Measles, Rubella, and Mumps
  6. Conducting regular visits by the self-assessment team to follow on the quality of vaccination delivery service 
  7. Continuous collaboration with UNICEFand WHO to follow-up on updates related to immunization worldwide and ensuring implementation in Lebanon considering national and international commitments
  8. Continuous collaboration with the private sector (General Practictioners and Pediatricians) to ensure vaccination for all children in Lebanon, particularly during immunization campaigns and routine immunization.
     
    ...
    120
    ...
ATC Name B/G Ingredients Dosage Form Price
L01FD01 KANJINTI BioTech Trastuzumab - 420mg 420mg Injectable powder for concentrate for solution 79,305,881 L.L
L01FD02 PERJETA 420MG BioTech Pertuzumab - 420mg/14ml 420mg/14ml Injectable concentrate for solution L.L
L01FD02 PERJETA 420MG BioTech Pertuzumab - 420mg/14ml 420mg/14ml Injectable concentrate for solution 220,054,714 L.L
L01FD02 PERTUVIA BioTech Pertuzumab - 420mg/14ml 420mg/14ml Injectable concentrate for solution 147,592,404 L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 100mg 100mg Injectable powder for concentrate for solution L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 160mg 160mg Injectable powder for concentrate for solution L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 100mg 100mg Injectable powder for concentrate for solution 135,545,977 L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 160mg 160mg Injectable powder for concentrate for solution 216,872,714 L.L
L01FD04 ENHERTU BioTech Trastuzumab deruxtecan - 100mg 100mg Injectable powder for concentrate for solution 178,517,964 L.L
L01FE01 ERBITUX BioTech Cetuximab - 100mg/20ml 100mg/20ml Injectable solution L.L
L01FE01 ERBITUX BioTech Cetuximab - 100mg/20ml 100mg/20ml Injectable solution 24,952,249 L.L
L01FE02 VECTIBIX BioTech Panitumumab - 400mg/20ml 400mg/20ml Injectable concentrated solution L.L
L01FE02 VECTIBIX BioTech Panitumumab - 100mg/5ml 100mg/5ml Injectable concentrated solution L.L
L01FE02 VECTIBIX BioTech Panitumumab - 400mg/20ml 400mg/20ml Injectable concentrated solution 147,763,999 L.L
L01FE02 VECTIBIX BioTech Panitumumab - 100mg/5ml 100mg/5ml Injectable concentrated solution 40,364,800 L.L
L01FF01 OPDIVO BioTech Nivolumab - 100mg/10ml 100mg/10ml Injectable solution L.L
L01FF01 OPDIVO BioTech Nivolumab - 40mg/4ml 40mg/4ml Injectable solution L.L
L01FF01 OPDIVO BioTech Nivolumab - 100mg/10ml 100mg/10ml Injectable solution 117,224,380 L.L
L01FF01 OPDIVO BioTech Nivolumab - 40mg/4ml 40mg/4ml Injectable solution 51,234,726 L.L
L01FF02 KEYTRUDA BioTech Pembrolizumab - 100mg/4ml 100mg/4ml Injectable solution L.L
L01FF02 KEYTRUDA BioTech Pembrolizumab - 100mg/4ml 100mg/4ml Injectable solution 241,744,802 L.L
L01FF03 IMFINZI BioTech Durvalumab - 500mg/10ml 500mg/10ml Injectable solution L.L
L01FF03 IMFINZI BioTech Durvalumab - 500mg/10ml 500mg/10ml Injectable solution L.L
L01FF03 IMFINZI BioTech Durvalumab - 500mg/10ml 500mg/10ml Injectable solution 227,939,689 L.L
L01FF03 IMFINZI BioTech Durvalumab - 500mg/10ml 500mg/10ml Injectable solution 227,939,689 L.L
L01FF03 IMFINZI BioTech Durvalumab - 120mg/2.4ml 120mg/2.4ml Injectable solution 59,776,110 L.L
L01FF03 IMFINZI BioTech Durvalumab - 120mg/2.4ml 120mg/2.4ml Injectable solution 59,776,110 L.L
L01FF04 BAVENCIO BioTech Avelumab - 200mg/10ml 200mg/10ml Injectable concentrate for solution L.L
L01FF04 BAVENCIO BioTech Avelumab - 200mg/10ml 200mg/10ml Injectable concentrate for solution 104,075,577 L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1200mg 1200mg Injectable concentrate for solution L.L
    ...
    120
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025